Evidence map›Paper›PMID 40370439›Full record

ArticleFrontiers in immunology2025

The CD38

Qiuyue Long, Shixu Song, Jianbo Xue, Wenyi Yu, Yaolin Zheng, Jiwei Li, Jing Wu, Xiaoyi Hu, Mingzheng Jiang, Hongli Ye and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Peripheral Immune Remodeling After Spinal Cord Injury: Marked by Expansion of CD38Neurology(R) neuroimmunology & neuroinflammation · 2026
    Observational
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Qiuyue Long *Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Shixu Song *Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Jianbo Xue *Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Wenyi YuDepartment of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Yaolin ZhengDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Jiwei LiDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Jing WuDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xiaoyi HuInstitute of Chest and Lung Diseases, Xiang'an Hospital of Xiamen University, Xiamen, China.
Mingzheng JiangDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Hongli YeDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Binghan ZhengDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Minghui WangDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Fangfang WuDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Ke LiDepartment of Critical Care Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Zhancheng GaoDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yali ZhengDepartment of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic remains a global health challenge. Severe cases often respond poorly to standard treatments, highlighting the necessity for novel therapeutic targets and early predictive biomarkers. Methods: We utilized flow cytometry to analyze peripheral immune cells from healthy, bacterial pneumonia patients, and COVID-19 patients. The expansion of activated T cells (CD38 Results: We revealed a significant increase in CD38 Conclusions: We identified the selective expansion of CD38

Indexed as

ADP-ribosyl Cyclase 1COVID-19HLA-DR AntigensSARS-CoV-2AdultAgedApyraseFemaleHumansLymphocyte ActivationMaleMembrane GlycoproteinsMiddle AgedPrognosisSeverity of Illness IndexSingle-Cell AnalysisADP-ribosyl Cyclase 1ApyraseCD38 protein, humanENTPD1 protein, humanHLA-DR AntigensMembrane GlycoproteinsCD38+HLA-DR+ T cellsCOVID-19mortality risk factorsingle-cell transcriptomicsT cells

Identifiers

PMID40370439
PMCPMC12074963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.